Literature DB >> 30025745

Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A pooled analysis of randomized controlled trials.

Chelsia Gillis1, Tanis R Fenton2, Tolulope T Sajobi3, Enrico Maria Minnella4, Rashami Awasthi4, Sarah-Ève Loiselle5, A Sender Liberman6, Barry Stein6, Patrick Charlebois6, Francesco Carli4.   

Abstract

BACKGROUND & AIMS: Preservation of lean body mass is an important cancer care objective. The capacity for prehabilitation interventions to modulate the lean body mass (LBM) of colorectal cancer patients before and after surgery is unknown.
METHODS: A pooled analysis of two randomized controlled trials of trimodal prehabilitation vs. trimodal rehabilitation at a single university-affiliated tertiary center employing Enhanced Recovery After Surgery (ERAS) care was conducted. The prehabilitation interventions included exercise, nutrition, and anxiety-reduction elements that began approximately four weeks before surgery and continued for eight weeks after surgery. The rehabilitation interventions were identical to the prehabilitation interventions but were initiated only after surgery. Body composition, measured using multifrequency bioelectrical impedance analysis, was recorded at baseline, pre-surgery, 4 and 8 weeks after surgery. The primary outcome was change in LBM before and after colorectal surgery for cancer. A mixed effects regression model was used to estimate changes in body mass and body composition over time controlling for age, sex, baseline body mass index (BMI), baseline six-minute walk test (6MWT), and postoperative compliance to the interventions. NCT02586701 &NCT01356264.
RESULTS: Pooled data included 76 patients who followed prehabilitation and 63 patients who followed rehabilitation (n = 139). Neither group experienced changes in preoperative LBM. Compared to rehabilitated patients, prehabilitated patients had significantly more absolute and relative LBM at four and eight-weeks post-surgery in models controlling for age, sex, baseline BMI, baseline 6MWT, and compliance to the postoperative intervention.
CONCLUSION: Trimodal prehabilitation attenuated the post-surgical LBM loss compared to the loss observed in patients who received the rehabilitation intervention. Patients who receive neither intervention (i.e., standard of care) would be likely to lose more LBM. Offering a prehabilitation program to colorectal cancer patients awaiting resection is a useful strategy to mitigate the impact of the surgical stress response on lean tissue in an ERAS setting, and, in turn, might have a positive impact on the cancer care course. CLINICAL TRIAL REGISTRATION: NCT02586701 &NCT01356264 (clinicaltrials.gov).
Copyright © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Body composition; ERAS; LBM; Prehab; Preoperative; Surgical preparation

Mesh:

Year:  2018        PMID: 30025745     DOI: 10.1016/j.clnu.2018.06.982

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  20 in total

Review 1.  Perioperative body composition changes in the multimodal treatment of gastrointestinal cancer.

Authors:  Toru Aoyama
Journal:  Surg Today       Date:  2019-04-26       Impact factor: 2.549

2.  Use of Functional Assessment to Define Therapeutic Goals and Treatment.

Authors:  Kevin P High; Susan Zieman; Jerry Gurwitz; Carl Hill; Jennifer Lai; Thomas Robinson; Mara Schonberg; Heather Whitson
Journal:  J Am Geriatr Soc       Date:  2019-05-13       Impact factor: 5.562

3.  Engagement and Adherence with a Web-Based Prehabilitation Program for Patients Awaiting Abdominal Colorectal Surgery.

Authors:  Elizabeth Shelton; Nicolas B Barreto; Serena Bidwell; Margaret Folk-Tolbert; Andrew Shelton; Amber W Trickey; Cindy J Kin
Journal:  J Gastrointest Surg       Date:  2021-10-19       Impact factor: 3.452

Review 4.  Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery.

Authors:  Charlotte Jl Molenaar; Stefan J van Rooijen; Hugo Jp Fokkenrood; Rudi Mh Roumen; Loes Janssen; Gerrit D Slooter
Journal:  Cochrane Database Syst Rev       Date:  2022-05-19

5.  Lessons learned from a pilot randomized clinical trial of home-based exercise prescription before allogeneic hematopoietic cell transplantation.

Authors:  William A Wood; M Weaver; A E Smith-Ryan; E D Hanson; T C Shea; C L Battaglini
Journal:  Support Care Cancer       Date:  2020-02-28       Impact factor: 3.603

6.  Organization of Multidisciplinary Cancer Care for the Surgical Patient: Role of Anesthesiologists.

Authors:  Elizabeth F Rieth; Gregory W Fischer; Anoushka M Afonso
Journal:  Curr Anesthesiol Rep       Date:  2018-10-08

Review 7.  Nutrition Care Process Model Approach to Surgical Prehabilitation in Oncology.

Authors:  Chelsia Gillis; Leslee Hasil; Popi Kasvis; Neil Bibby; Sarah J Davies; Carla M Prado; Malcolm A West; Clare Shaw
Journal:  Front Nutr       Date:  2021-06-24

8.  Effect of home-based prehabilitation in an enhanced recovery after surgery program for patients undergoing colorectal cancer surgery during the COVID-19 pandemic.

Authors:  Francisco López-Rodríguez-Arias; Luis Sánchez-Guillén; Verónica Aranaz-Ostáriz; Daniel Triguero-Cánovas; Sandra Lario-Pérez; Xavier Barber-Valles; Francisco J Lacueva; José M Ramirez; Antonio Arroyo
Journal:  Support Care Cancer       Date:  2021-06-24       Impact factor: 3.603

9.  Physical therapy prehabilitation on a reverse total shoulder replacement candidate: a case study.

Authors:  James F Villers; Jacob Burch; Mark Scheller; Han-Hung Huang
Journal:  J Phys Ther Sci       Date:  2020-02-14

10.  Frailty Assessment and Prehabilitation Before Complex Spine Surgery in Patients With Degenerative Spine Disease: A Narrative Review.

Authors:  Basma Mohamed; Ramani Ramachandran; Ferenc Rabai; Catherine C Price; Adam Polifka; Daniel Hoh; Christoph N Seubert
Journal:  J Neurosurg Anesthesiol       Date:  2021-08-05       Impact factor: 3.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.